The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis
- 29 February 2004
- journal article
- research article
- Published by Elsevier in Best Practice & Research Clinical Rheumatology
- Vol. 18 (1) , 59-80
- https://doi.org/10.1016/j.berh.2003.09.010
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- Anti-TNF-?-induced systemic lupus syndromeClinical Rheumatology, 2003
- Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug AdministrationArthritis & Rheumatism, 2002
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritisArthritis & Rheumatism, 2000
- Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor αArthritis & Rheumatism, 1993
- Construction and initial characterization of a mouse-human chimeric anti-TNF antibodyMolecular Immunology, 1993
- TNFα—A PIVOTAL ROLE IN RHEUMATOID ARTHRITIS?Rheumatology, 1992
- Tumour necrosis factor in synovial exudates.Annals of the Rheumatic Diseases, 1988
- Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxinNature, 1984
- Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activityNature, 1984